Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Carissa Treptow"'
Autor:
Frank A. Lattuca, Jeremiah Moore, Carissa Treptow, Kendra Delibert, Andrea Baran, Frank Akwaa
Publikováno v:
Thrombosis Update, Vol 10, Iss , Pp 100129- (2023)
Introduction: Patients with cancer have an increased risk of developing venous thromboembolism (VTE), and subsequently a higher risk of bleeding secondary to anticoagulants. Low-molecular weight heparin (LMWH) has been the standard of care for these
Externí odkaz:
https://doaj.org/article/5102c200bac84c36ac09d7f9865352ba
Autor:
Patrick W. Burke, Stephen M Clark, Marissa Olson, Tapan M. Kadia, Dale L. Bixby, Carissa Treptow, Shawn Griffin, Bernard L. Marini, Kelley L Ratermann, Caitlin R. Rausch, Lydia L. Benitez, Mallory Crain, Anthony J. Perissinotti, Kristen Pettit, Michael Filtz, Jeff Klaus
Publikováno v:
Leukemia & Lymphoma. 62:2184-2192
Liposomal daunorubicin/cytarabine (CPX-351) gained FDA approval for secondary AML after demonstrating improved outcomes over daunorubicin and cytarabine (7 + 3). A number of study limitations prompted a comparison of safety/efficacy of CPX-351 agains
Publikováno v:
Transplantation and Cellular Therapy. 28:S109
Autor:
Anthony J. Perissinotti, Carissa Treptow, Stephen M Clark, Patrick W. Burke, Kelley L Ratermann, Bernard L. Marini, Michael Filtz, Jeff Klaus, Kristen Pettit, Dale L. Bixby, Lydia L. Benitez, Caitlin R. Rausch, Shawn Griffin, Mallory Crain, Marissa Olson
Publikováno v:
Blood. 134:2639-2639
BACKGROUND Secondary AML (sAML) that develops after an antecedent hematologic disorder or exposure to genotoxic therapy is associated with a poor prognosis and historical long-term survival rates of 5-10% (Granfeldt Østgård et al. 2015). Liposomal
Autor:
Karim Welaya, Manidhar Reddy Lekkala, Dwight Hettler, Julie Ann Berkhof, Bahar Moftakhar, Karen J. Abbas, Jason H. Mendler, Megan Ann Baumgart, Dilip Sankar Babu, Titas Banerjee, Carissa Treptow, Nabeel Badri
Publikováno v:
Journal of Clinical Oncology. 37:12-12
12 Background: Inpatient mortality, defined as death within 30 days of an acute hospital admission, is often used as a quality benchmark for healthcare institutions and is an important metric for evaluating quality of care of patients with advanced m